IDEAYA Biosciences’ (IDYA) “Sell (D-)” Rating Reiterated at Weiss Ratings

IDEAYA Biosciences (NASDAQ:IDYA)‘s stock had its “sell (d-)” rating reissued by Weiss Ratings in a research note issued on Wednesday,Weiss Ratings reports.

Several other equities analysts have also recently weighed in on IDYA. Barclays started coverage on IDEAYA Biosciences in a research report on Thursday, September 4th. They issued an “overweight” rating and a $40.00 price target for the company. Citigroup restated a “buy” rating on shares of IDEAYA Biosciences in a research report on Tuesday, September 9th. Wall Street Zen upgraded IDEAYA Biosciences from a “sell” rating to a “hold” rating in a research report on Friday, October 3rd. JPMorgan Chase & Co. boosted their target price on IDEAYA Biosciences from $72.00 to $74.00 and gave the stock an “overweight” rating in a research report on Wednesday, September 3rd. Finally, Royal Bank Of Canada boosted their target price on IDEAYA Biosciences from $36.00 to $38.00 and gave the stock an “outperform” rating in a research report on Tuesday, September 9th. Fourteen equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $43.36.

IDEAYA Biosciences Stock Performance

Shares of NASDAQ IDYA opened at $26.84 on Wednesday. The stock has a market cap of $2.35 billion, a PE ratio of -7.08 and a beta of 0.14. IDEAYA Biosciences has a fifty-two week low of $13.45 and a fifty-two week high of $32.67. The stock has a fifty day moving average of $25.16 and a 200-day moving average of $21.66.

IDEAYA Biosciences (NASDAQ:IDYA) last announced its quarterly earnings results on Tuesday, August 5th. The company reported ($0.88) earnings per share for the quarter, missing the consensus estimate of ($0.85) by ($0.03). The firm had revenue of $6.00 million during the quarter, compared to the consensus estimate of $3.48 million. The business’s quarterly revenue was up NaN% compared to the same quarter last year. During the same period in the previous year, the business posted ($0.68) EPS. On average, sell-side analysts predict that IDEAYA Biosciences will post -3.07 EPS for the current year.

Institutional Investors Weigh In On IDEAYA Biosciences

Several hedge funds have recently added to or reduced their stakes in IDYA. Millennium Management LLC lifted its stake in IDEAYA Biosciences by 345.2% during the first quarter. Millennium Management LLC now owns 547,637 shares of the company’s stock worth $8,970,000 after purchasing an additional 424,625 shares during the last quarter. Ensign Peak Advisors Inc lifted its stake in IDEAYA Biosciences by 126.4% during the second quarter. Ensign Peak Advisors Inc now owns 741,833 shares of the company’s stock worth $15,593,000 after purchasing an additional 414,189 shares during the last quarter. Fiera Capital Corp lifted its stake in IDEAYA Biosciences by 26.6% during the second quarter. Fiera Capital Corp now owns 1,532,269 shares of the company’s stock worth $32,208,000 after purchasing an additional 322,404 shares during the last quarter. Algert Global LLC bought a new stake in IDEAYA Biosciences during the first quarter worth about $5,024,000. Finally, Nuveen LLC bought a new stake in IDEAYA Biosciences during the first quarter worth about $4,706,000. Institutional investors own 98.29% of the company’s stock.

IDEAYA Biosciences Company Profile

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.